Replicor to Disclose Late Breaking HBV Clinical Data at AASLD 2016

NEW YORK–(BUSINESS WIRE)– Replicor Inc., a privately held biopharmaceutical company targeting a
cure for chronic hepatitis B and D patients, today announced that the
preliminary interim analysis from its latest REP 401 clinical trial has
been selected by the American Association for the Study of Liver Disease
(AASLD) for presentation during the late-breaking oral abstract session
at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.

The REP 401 protocol (NCT02565719)
is a randomized, controlled trial assessing the safety and efficacy of
its first in class HBsAg release inhibitor, REP 2139 and a REP 2139
derivative with improved plasma and tissue clearance (REP 2165) in
combination with tenofovir disoproxil fumarate (TDF) and pegylated
interferon alpha 2a (peg-IFN) in treatment naïve patients with chronic
HBeAg negative HBV infection. The selection of Replicor’s clinical data
for presentation during the late breaking oral abstract session on
November 15^th, 2016 highlights the recognition of NAP-based
therapy as an important new approach for achieving functional cure in
patients with chronic HBV.

Complete 6 month follow-up data from the REP 301 protocol (NCT02233075)
assessing the safety and efficacy of REP 2139 in combination with
peg-IFN in patients with chronic HBV / HDV co-infection will also be
presented during the poster session on November 14^th, 2016.

These presentations will expand on the existing clinical data
demonstrating the unique ability of NAP-based combination therapy to
eliminate serum HBsAg and to achieve functional cure in patients with
HBV and HBV / HDV co-infection.

Replicor’s presentations from AASLD 2016 will be available on the
company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations.
For further information about the 2016 AASLD Meeting visit: http://www.aasld.org/events-professional-development/liver-meeting.

About Replicor

Replicor is a privately held biopharmaceutical company with the most
advanced animal and human clinical data in the development of the cure
for HBV and HDV. The company is dedicated to accelerating the
development of an effective treatment for patients with HBV and HBV/HDV
co-infection. For further information about Replicor please visit our
website at www.replicor.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005362/en/